Testing a drug to shrink high-risk prostate cancer before surgery
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests whether a hormone-blocking drug called darolutamide can shrink aggressive prostate cancer before surgery. Researchers will also use a special blood test to predict who benefits most from the treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Biopsy-confirmed prostate cancer that is considered high-risk based on specific grades and MRI imaging
- You are a candidate for prostate removal surgery (radical prostatectomy)
- An MRI of your prostate done within the last 3 months
- Good overall health status (able to handle the treatment with minimal limitations)
- Able to take darolutamide for 90–120 days before surgery
- Willing to use contraception if sexually active during the treatment period
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two oral hormone drugs (darolutamide and relugolix) given before prostate removal surgery for men with high-risk prostate cancer. The goal is to see if this combination shrinks the tumor and improves treatment outcomes.
This study tests whether giving the drug darolutamide (with or without standard hormone therapy) before surgery helps shrink high-risk prostate cancer and reduce the chance of it coming back. If you qualify, you would receive the study treatment for a few months before your planned prostate removal surgery.
This trial tests a medicine called darolutamide taken with hormone therapy (ADT) before surgery to remove the prostate. It is for men with a high-risk prostate cancer that has not spread to other parts of the body.
This trial tests giving a new hormone-blocking drug (darolutamide) plus standard hormone therapy before surgery for men with high-risk prostate cancer that has not spread. The goal is to see if this approach improves outcomes.
This trial tests a combination of two hormone therapies (darolutamide plus androgen deprivation therapy) given after surgery to remove the prostate, to see if it helps prevent the cancer from coming back in men with high-risk prostate cancer. The goal is to see if this treatment can keep the cancer from spreading or returning.
This trial tests a new combination of two drugs given before surgery to shrink high-risk prostate cancer. The goal is to see if this approach can improve outcomes for patients whose cancer is aggressive but has not spread.
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.